140 related articles for article (PubMed ID: 37679749)
21. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients.
Romano M; Pontikaki I; Gattinara M; Ardoino I; Donati C; Boracchi P; Meroni PL; Gerloni V
Reumatismo; 2014 Mar; 65(6):278-85. PubMed ID: 24705031
[TBL] [Abstract][Full Text] [Related]
22. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
23. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry.
Hahn T; Daymont C; Beukelman T; Groh B; Hays K; Bingham CA; Scalzi L;
Pediatr Rheumatol Online J; 2022 Nov; 20(1):107. PubMed ID: 36434731
[TBL] [Abstract][Full Text] [Related]
24. The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.
Janow G; Schanberg LE; Setoguchi S; Hasselblad V; Mellins ED; Schneider R; Kimura Y;
J Rheumatol; 2016 Sep; 43(9):1755-62. PubMed ID: 27307527
[TBL] [Abstract][Full Text] [Related]
25. Disease course and obstetric outcomes of pregnancies in juvenile idiopathic arthritis: are there any differences among disease subtypes? A single-centre retrospective study of prospectively followed pregnancies in a dedicated pregnancy clinic.
García-Fernández A; Gerardi MC; Crisafulli F; Filippini M; Fredi M; Gorla R; Lazzaroni MG; Lojacono A; Nalli C; Ramazzotto F; Taglietti M; Zanardini C; Zatti S; Franceschini F; Tincani A; Andreoli L
Clin Rheumatol; 2021 Jan; 40(1):239-244. PubMed ID: 32945981
[TBL] [Abstract][Full Text] [Related]
26. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial.
Gerss J; Tedy M; Klein A; Horneff G; Miranda-Garcia M; Kessel C; Holzinger D; Stanevica V; Swart JF; Cabral DA; Brunner HI; Foell D
Ann Rheum Dis; 2022 Jul; 81(7):990-997. PubMed ID: 35260388
[TBL] [Abstract][Full Text] [Related]
27. Similarities in clinical course and outcome between juvenile idiopathic arthritis (JIA)-associated and ANA-positive idiopathic anterior uveitis: data from a population-based nationwide study in Germany.
Heiligenhaus A; Klotsche J; Niewerth M; Horneff G; Ganser G; Haas JP; Minden K
Arthritis Res Ther; 2020 Apr; 22(1):81. PubMed ID: 32293540
[TBL] [Abstract][Full Text] [Related]
28. Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).
Nigrovic PA; Beukelman T; Tomlinson G; Feldman BM; Schanberg LE; Kimura Y;
Clin Trials; 2018 Jun; 15(3):268-277. PubMed ID: 29542334
[TBL] [Abstract][Full Text] [Related]
29. Individual and environmental determinants associated with longer times to access pediatric rheumatology centers for patients with juvenile idiopathic arthritis, a JIR cohort study.
Chausset A; Lambert C; Belot A; Merlin E; Cannizzaro E; Kone-Paut I; Ballot C; Devauchelle V; Poignant S; Carlomagno R; Lohse A; Barbier C; Despert V; Carbasse A; Sparsa L; Adank E; Vanoni F; Reumaux H; Pillet P; Kaiser D; Hofer M; Freychet C; Schott AM
Pediatr Rheumatol Online J; 2023 Mar; 21(1):24. PubMed ID: 36918902
[TBL] [Abstract][Full Text] [Related]
30. Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children.
Tiller G; Buckle J; Allen R; Munro J; Gowdie P; Cox A; Akikusa J
Pediatr Rheumatol Online J; 2018 Nov; 16(1):69. PubMed ID: 30413164
[TBL] [Abstract][Full Text] [Related]
31. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
Klotsche J; Minden K; Niewerth M; Horneff G
Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
[TBL] [Abstract][Full Text] [Related]
32. Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course.
Ključevšek D; Emeršič N; Toplak N; Avčin T
Pediatr Rheumatol Online J; 2017 May; 15(1):38. PubMed ID: 28506237
[TBL] [Abstract][Full Text] [Related]
33. Course, Outcome and Complications in Children with Systemic Onset Juvenile Idiopathic Arthritis.
Dewoolkar M; Cimaz R; Chickermane PR; Khubchandani RP
Indian J Pediatr; 2017 Apr; 84(4):294-298. PubMed ID: 28229369
[TBL] [Abstract][Full Text] [Related]
34. Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?
Greenwald AG; Zakerzadeh A; Laxer RM; Schneider R; Cameron B; Feldman B; Spiegel L; Tse SM; Silverman ED
Clin Exp Rheumatol; 2013; 31(4):645-52. PubMed ID: 23622111
[TBL] [Abstract][Full Text] [Related]
35. Description of active joint count trajectories in juvenile idiopathic arthritis.
Berard RA; Tomlinson G; Li X; Oen K; Rosenberg AM; Feldman BM; Yeung RS; Bombardier C
J Rheumatol; 2014 Dec; 41(12):2466-73. PubMed ID: 25274882
[TBL] [Abstract][Full Text] [Related]
36. Cumulative Damage in Juvenile Idiopathic Arthritis: A Multicenter Study From the Pediatric Rheumatology Arab Group.
Al-Mayouf SM; Hashad S; Khawaja K; Alrasheedi A; Abdwani R; Abushhaiwia A; AlSuwaiti M; Alzyoud R; Al Abrawi S; Asiri A; Alshaikh M; Sharif E; Muzaffer M; Alsewairi W; Zlenti M; Kawaja E; Almutairi M; Majeed M; Lotfy H; AlMarri M; Almutairi N;
Arthritis Care Res (Hoboken); 2021 Apr; 73(4):586-592. PubMed ID: 32886859
[TBL] [Abstract][Full Text] [Related]
37. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
[TBL] [Abstract][Full Text] [Related]
38. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.
Guzman J; Oen K; Tucker LB; Huber AM; Shiff N; Boire G; Scuccimarri R; Berard R; Tse SM; Morishita K; Stringer E; Johnson N; Levy DM; Duffy KW; Cabral DA; Rosenberg AM; Larché M; Dancey P; Petty RE; Laxer RM; Silverman E; Miettunen P; Chetaille AL; Haddad E; Houghton K; Spiegel L; Turvey SE; Schmeling H; Lang B; Ellsworth J; Ramsey S; Bruns A; Campillo S; Benseler S; Chédeville G; Schneider R; Yeung R; Duffy CM;
Ann Rheum Dis; 2015 Oct; 74(10):1854-60. PubMed ID: 24842571
[TBL] [Abstract][Full Text] [Related]
39. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review.
Davies R; Gaynor D; Hyrich KL; Pain CE
Semin Arthritis Rheum; 2017 Apr; 46(5):584-593. PubMed ID: 27914689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
